Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DuPont's Innohep Anticoagulant Approved With Once-Daily Dosing Regimen

Executive Summary

DuPont's low molecular weight heparin Innohep will enter the market as the only treatment with once-daily dosing for all patients with deep vein thrombosis. Other LMWHs have a mix of recommended dosages, which may include once-daily administration.

You may also be interested in...



DuPont Innohep

FDA objects to July 18 tinzaparin press release for implying that "Innohep is indicated for use in all [deep vein thrombosis] patients, that it is approved for monotherapy and that it is the only low molecular weight heparin that is administered once-a-day." Innohep was approved by FDA July 14 for acute DVT with or without pulmonary embolism in combination with warfarin (1"The Pink Sheet" July 24, p. 13)

DuPont Innohep

FDA objects to July 18 tinzaparin press release for implying that "Innohep is indicated for use in all [deep vein thrombosis] patients, that it is approved for monotherapy and that it is the only low molecular weight heparin that is administered once-a-day." Innohep was approved by FDA July 14 for acute DVT with or without pulmonary embolism in combination with warfarin (1"The Pink Sheet" July 24, p. 13)

Lovenox Cost-Effectiveness Over Heparin Highlighted In ACC/AHA Guidelines

The cost-effectiveness of Rhone-Poulenc Rorer's Lovenox relative to unfractionated heparin in the treatment of unstable angina/non-Q-wave myocardial infarction is discussed in the 1999 American College of Cardiology/ American Heart Association practice guidelines.

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel